Rauh R, Soell D, Haerteis S, Diakov A, Nesterov V, Krueger B, Sticht H, Korbmacher C. A mutation in the ␤-subunit of ENaC identified in a patient with cystic fibrosis-like symptoms has a gain-of-function effect. Am J Physiol Lung Cell Mol Physiol 304: L43-L55, 2013. First published October 19, 2012 doi:10.1152/ajplung.00093.2012In some patients with atypical cystic fibrosis (CF), only one allele of the CF transmembrane conductance regulator (CFTR) gene is affected. Mutations of the epithelial sodium channel (ENaC) may contribute to the pathophysiology of the disease in these patients. To functionally characterize a mutation in the ␤-subunit of ENaC (␤V348M) recently identified in a patient with severe CF-like symptoms (Mutesa et al. 2009 ), we expressed wild-type (wt) ␣␤␥ENaC or mutant ␣␤V348M␥ENaC in Xenopus laevis oocytes. The ␤V348M mutation stimulated amiloridesensitive whole-cell current (⌬Iami) by ϳ40% but had no effect on surface expression or single-channel conductance of ENaC. Instead the mutation increased channel open probability (Po). Proteolytic activation of mutant ENaC by chymotrypsin was reduced compared with that of wt ENaC (ϳ3.0-fold vs. ϳ4.2-fold), which is consistent with the increased baseline Po of mutant ENaC. Similarly, the ENaC activator S3969 stimulated mutant ENaC currents to a lesser degree (by ϳ2.6-fold) than wt ENaC currents (by ϳ3.5-fold). The gain-offunction effect of the ␤V348M mutation was confirmed by whole-cell current measurements in HEK293 cells transiently transfected with wt or mutant ENaC. Computational channel modeling in combination with functional expression of different ␤V348 mutants in oocytes suggests that the ␤V348M mutation increases channel Po by destabilizing the closed channel state. Our findings indicate that the gain-offunction effect of the ␤V348M mutation may contribute to CF pathophysiology by inappropriately increasing sodium and fluid absorption in the respiratory tract.
gain-of-function mutation; Xenopus laevis oocyte expression system; electrophysiology; computational channel modeling; sodium transport in cystic fibrosis; epithelial sodium channel CYSTIC FIBROSIS (CF) is a common autosomal recessive hereditary disease that is usually caused by mutations in the CF transmembrane conductance regulator (CFTR) gene (46) . The CFTR gene encodes a Cl Ϫ channel, which is found in the apical membrane of a wide range of epithelial cells (50) . Defective CFTR results in reduced apical Cl Ϫ conductance, a typical hallmark of CF epithelia. Patients with CF present with diverse symptoms, e.g., chronic sinopulmonary disease, exocrine pancreatic insufficiency, failure to thrive, or congenital bilateral absence of the vas deferens (13) . The large heterogeneity of symptoms and a poor genotype/phenotype correlation suggest that modifier genes exist (12) . The genes encoding the ␤-and ␥-subunits of the epithelial sodium channel (ENaC) have been reported to be potential modifier genes in CF (53) . Moreover, in some patients with a milder CF phenotype (so-called atypical CF), no CFTR mutations could be identified or only one allele was affected (1, 51) . Interestingly, the identified mutations of ENaC include gain-of-function as well as loss-of-function mutations (1, 24, 44, 51) , which makes it challenging to develop a concept of how ENaC function may modify CF.
ENaC is the rate-limiting step for sodium absorption in a variety of sodium-absorbing epithelia, e.g., in the lung, distal nephron, distal colon, and sweat and salivary ducts (18, 19, 29) . It is a member of the ENaC/degenerin family of nonvoltage-gated ion channels. In epithelial tissues, the channel is composed of three homologous subunits (␣, ␤, ␥). Each subunit has cytosolic NH 2 and COOH termini and two transmembrane domains that are connected by a large extracellular loop (29) . The published crystal structure of the related acid-sensing ion channel (ASIC1) (26, 55) and recent atomic force microscopy data (54) suggest that ENaC is a heterotrimer. In respiratory epithelia, a fine balance between Na ϩ absorption via ENaC and Cl Ϫ secretion via CFTR is thought to be necessary to maintain an appropriate airway surface liquid (ASL) volume, which is important for pulmonary mucus clearance (3, 16) . In classical CF with defective CFTR, the failure to secrete Cl Ϫ is probably the main cause for ASL volume depletion, which reduces mucociliary clearance and favors bacterial infections. In addition, enhanced sodium absorption may contribute to ASL volume depletion and may aggravate CF symptoms. Indeed, higher ENaC activity has recently been demonstrated in freshly isolated murine alveolar epithelial cells when CFTR expression was reduced or totally absent (35) . Importantly, transgenic mice overexpressing ␤-ENaC in the airways develop a CF-like pulmonary phenotype (37) . This demonstrates that, at least in mice, enhanced Na ϩ absorption in respiratory epithelia is sufficient to cause CF-like disease. Similarly, knockout of Nedd4 -2, a negative regulator of ENaC expression at the plasma membrane, also causes CF-like pulmonary symptoms in mice (2, 30) . Preventive amiloride therapy reduces morbidity and mortality in ␤-ENaC-overexpressing (59) and Nedd4 -2 knockout (30) mice. These findings support the hypothesis that ENaC gain-of-function mutations may contribute to CF pathophysiology. Recent studies of a porcine model showed that excised and cultured CFTR Ϫ/Ϫ and CFTR ⌬F508/⌬F508 airway epithelia did not hyperabsorb Na ϩ (9) . Moreover, it has been reported that, in differentiated primary cultures of human CF and non-CF respiratory epithelia, the Na ϩ channel inhibitor amiloride produced similar reductions in transepithelial conductance and Na ϩ absorption, indicating that Na ϩ conductance in CF epithelia did not exceed that in non-CF epithelia (25) . Thus at present it remains a matter of debate whether enhanced ENaC function contributes to the pathophysiology of CF. It is conceivable that ENaC hyperactivity may play a role in only a subset of patients with CF.
Recently, a mutation in the ␤-subunit (␤V348M) of ENaC has been identified in a patient with severe CF-like symptoms (recurrent respiratory infections, lung colonization by Pseudomonas aeruginosa, gastrointestinal symptoms, failure to thrive, diabetes mellitus, and protein energy malnutrition) (39) . Moreover, the ␤V348 residue has been reported to be critical for the stimulatory effect of the novel ENaC activator S3969 (36) . These findings suggest that this residue is functionally important and that the identified mutation is likely to alter channel properties. The aim of the present study was to investigate the effects of the ␤V348M mutation on ENaC function.
MATERIALS AND METHODS

Chemicals and solutions.
Unless stated otherwise, chemicals were from Sigma (Taufkirchen, Germany). 2-(trimethylammonium)ethyl methanethiosulphonate bromide (MTSET) was obtained from Toronto Research Chemicals (Toronto, Ontario, Canada); collagenase type II (CLS II), fetal bovine serum, sodium pyruvate and nonessential amino acids were from Biochrom (Berlin, Germany); and Modified Eagle's Medium was from PAA Laboratories (Cölbe, Germany). S3969 (36) was synthesized as described previously (24) . The solutions used were: OR2 for isolation of oocytes (in mM: 82.5 NaCl, 2 KCl, 1 MgCl 2, 5 HEPES, pH 7.4 with NaOH), a low-Na ϩ -containing solution for oocyte incubation (in mM: 87 NMDG-Cl, 9 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2, 5 HEPES, 100 U/ml penicillin, 100 g/ml streptomycin, pH 7.4 with Tris), and ND96 as the bath solution for two-electrode voltage-clamp experiments (in mM: 96 NaCl, 2 KCl, 1.8 CaCl 2, 1 MgCl2, 5 HEPES, pH 7.4 with Tris). Solutions used for outside-out patch-clamp procedures were: pipette solution (in mM: 90 K-gluconate, 5 NaCl, 2 Mg-ATP, 2 EGTA, 10 HEPES, pH 7.28 with Tris), low-sodium NMDG-Cl bath solution (in mM: 95 NMDG-Cl, 1 NaCl, 4 KCl, 1 MgCl 2, 1 CaCl2, 10 HEPES, pH 7.4 with Tris), and high-sodium bath solution (in mM: 95 NaCl, 4 KCl, 1 MgCl2, 1 CaCl2, 10 HEPES, pH 7.4 with Tris). Solutions used for whole-cell voltage clamp on HEK293 cells were: pipette solution [in mM: 130 CsCl, 2 Mg-ATP, 10 HEPES, 5 EGTA-Na (tetrasodium salt), 2 MgCl 2, pH 7.2 with Tris], and bath solution (in mM: 160 NaCl, 1 CaCl2, 2 MgCl2, 10 HEPES, pH 7.4 with Tris).
Plasmids. Full-length cDNAs for all human ENaC subunits were cloned in pcDNA3.1 as previously described (1) . Linearized plasmids were used as templates for cRNA synthesis using T7 RNA polymerases (mMessage mMachine; Ambion, Austin, TX). To minimize the risk of expression artifacts that may arise from differences in cRNA quality, cRNAs for wild-type (wt) and mutant ENaC were synthesized in parallel, and the experiments were performed using at least two different batches of cRNA. Point mutations were generated by site-directed mutagenesis (QuikChange Site-Directed Mutagenesis Kit; Stratagene, Amsterdam, Netherlands) and confirmed by sequence analysis.
Isolation of oocytes and injection of cRNA. Oocytes were obtained from adult female Xenopus laevis in accordance with German legislation, with approval by the animal welfare officer for the University of Erlangen-Nuremberg, and under the governance of the state veterinary health inspectorate. Animals were anesthetized in 0.2% MS222 (ethyl 3-aminobenzoate methanesulfonate salt). Ovarian lobes were obtained by partial ovariectomy, and oocytes were isolated by enzymatic digestion at 19°C for 3-4 h with 600 -700 U/ml collagenase type II dissolved in OR2 solution. Isolated oocytes were stored in ND96 supplemented with 100 U/ml penicillin and 100 g/ml streptomycin to prevent bacterial overgrowth until injection. Defolliculated stage V-VI oocytes were injected (Nanoject II automatic injector; Drummond, Broomall, PA) with 0.5 ng cRNA per subunit of ENaC. The cRNAs were dissolved in RNase-free water, and the total volume injected was 46 nl. To prevent excessive sodium loading of ENaC-expressing oocytes, the injected oocytes were stored until use in a low-Na ϩ -containing solution (supplemented with 100 U/ml penicillin and 100 g/ml streptomycin) at 19°C as previously described (21, 24, 44) .
HEK293 cell culture and transfection. HEK293 cells were cultured in Modified Eagle's Medium supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 1% nonessential amino acids, 100 U/ml penicillin, and 100 g/ml streptomycin. Cells were transfected with plasmids coding for ␣-, ␥-and ␤-or ␤V348M-ENaC 1 day after seeding at a level of ϳ60% confluence using X-treme Gene HP DNA transfection reagent (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's protocol. The transfection reagent was used in a ratio 1:4. pEGFP-C1 (Invitrogen, Darmstadt, Germany) was cotransfected to identify positively transfected cells in the patchclamp experiments using fluorescence microscopy. After transfection, medium was supplemented with amiloride (10 M) to avoid excessive sodium loading of the cells.
Two-electrode voltage clamp. Oocytes were routinely studied 1-2 days after injection using the two-electrode voltage-clamp technique as described previously (45, 58) . The oocytes were placed in a small experimental chamber and constantly superfused (2-3 ml/min) at room temperature with ND96 supplemented with amiloride (2 M). Bath solution exchanges were controlled by an ALA BPS-8 magnetic valve system in combination with a TIB14 interface (both HEKA, Lambrecht, Germany). Voltage-clamp experiments were performed using an OC-725C amplifier (Warner Instruments, Hamden, CT) interfaced via a LIH-1600 (HEKA) to a PC running PULSE 8.67 software (HEKA) for data acquisition and analysis. For continuous whole-cell current recordings, oocytes were routinely clamped at a holding potential of Ϫ60 mV. Amiloride-sensitive whole-cell currents (⌬Iami) were determined by washing out amiloride with amiloride-free ND96 and by subtracting the whole-cell current measured in the absence of amiloride from that measured in the presence. Downward current deflections in current traces correspond to inward currents, i.e., movement of positive charge into the cell.
Patch-clamp experiments on oocytes. Single-channel recordings in conventional outside-out patches were essentially performed as described previously (15, 44) . Oocytes were routinely studied 2-3 days after injection. Patch pipettes were pulled from borosilicate glass capillaries and had a tip diameter of ϳ1-1.5 m after fire polishing. Pipettes were filled with potassium gluconate pipette solution. Seals were routinely formed in a low-Na ϩ NMDG-Cl bath solution. In this bath solution, the pipette resistance averaged ϳ7 M⍀. After seal formation, the bath solution was changed to a high-Na ϩ solution. Outside-out patches were routinely voltage clamped at Ϫ70 mV, which is close to the calculated reversal potential of Cl Ϫ (ECl ϭ Ϫ77.2 mV) and K ϩ (EK ϭ Ϫ79.4 mV) under our experimental conditions. Experiments were performed at room temperature (ϳ23°C). The current level at which all channels are closed was determined in the presence of amiloride (2 M). Downward current deflections correspond to cell membrane inward currents, i.e., movement of positive charge from the extracellular side to the cytoplasmic side. Single-channel current data were filtered at 1 kHz and digitized at 3 kHz before refiltering at 50 Hz to calculate single-channel current amplitude and channel activity. The current level at which all channels are closed (closed level) was determined in the presence of amiloride (2 M). Binned amplitude histograms were used to determine the single-channel current amplitude (i) and to estimate channel activity as the product NP o, where N is the number of channels and Po is the single-channel open probability (14, 15, 33, 34) . To analyze channel gating, we calculated the number of channel transitions per second per apparent number of channels (Transitions ϫ s Ϫ1 ϫ Napp Ϫ1 ) (34) . Data analysis was performed using the program Patch for Windows written by Dr. Bernd Letz (HEKA Elektronik, Lambrecht/Pfalz, Germany).
Whole-cell patch-clamp experiments in HEK293 cells. Conventional whole-cell patch-clamp recordings from cultured HEK293 cells were performed at 37°C using an experimental protocol and setup essentially as described previously (41, 42) . Green fluorescent protein fluorescence was used to facilitate selection of successfully transfected cells. Only recordings with a clear amiloride response were included in the data analysis (ϳ20% of selected cells did not respond to amiloride). Pipettes were made from borosilicate glass and had a resistance of 3-4 M⍀. Seal resistance was 4 -10 G⍀, and series resistance (R s) was 5-8 M⍀. Membrane capacitance (Cm) and Rs were estimated using the automated capacitance compensation procedure of the EPC-9 amplifier. Rs was compensated by 70%; Cm ranged from 7 to 15 pF. Cells were voltage clamped at a holding potential of Ϫ60 mV. Current signals were filtered at 250 Hz and sampled at a rate of 1 kHz. For further analysis and presentation, they were routinely refiltered at 100 Hz. The amiloride-sensitive current (⌬I ami) was determined by subtracting the whole-cell current measured in the presence of amiloride from that measured in the absence of amiloride (2 M). Current density was calculated as the ratio of ⌬I ami to cell membrane capacitance.
Detection of ␤ENaC at the cell surface. Biotinylation experiments were performed essentially as described (14, 22, 23 ) using 30 oocytes per group. All biotinylation steps were performed on ice. Oocytes were incubated in biotinylation buffer [in mM: 10 triethanolamine, 150 NaCl, 2 CaCl 2, EZ-link sulfo-NHS-SSBiotin (1 mg/ml, pH 9.5; Pierce, Rockford, IL)] for 15 min with gentle agitation. The biotinylation reaction was stopped by washing the oocytes twice for 5 min with a quenching buffer (in mM: 192 glycine, 25 Tris, pH 7.5). Oocytes were lysed by passing them five times through a 27-gauge needle in lysis buffer (in mM: 500 NaCl, 5 EDTA, 50 Tris, pH 7.4) supplemented with a protease inhibitor cocktail (Complete Mini EDTA-free protease inhibitor cocktail tablets; Roche Diagnostics) according to manufacturer's instructions. The lysates were centrifuged for 10 min at 1,500 g. After addition of 0.5% Triton X-100 and 0.5% Igepal CA-630, supernatants were incubated for 20 min on ice, and 100 l of Immunopure immobilized Neutravidin beads (Pierce) were added. After overnight incubation at 4°C with overhead rotation, the tubes were centrifuged for 3 min at 1,500 g. Supernatants were removed and used for the detection of intracellular ␤ENaC. The remaining beads were washed three times with lysis buffer, and 100 l of 2ϫ SDS-PAGE sample buffer (Rotiload 1; Roth, Karlsruhe, Germany) were added. Samples were boiled for 5 min at 95°C and centrifuged for 3 min at 20,000 g before loading the supernatants on a 10% SDS-PAGE gel. Separated proteins were transferred onto a nitrocellulose membrane by semidry blotting and detected with a primary rabbit anti-human ␤ENaC antibody (1:10,000) (22) and a horseradish peroxidase-labeled secondary goat anti-rabbit antibody (1:50,000; Santa Cruz Biotechnology, Heidelberg, Germany). Absence of intracellular proteins was determined by monitoring the ␤-actin signal. Densitometric analysis was performed using ImageJ 1.38x (National Institutes of Health, Bethesda, MD).
ENaC modeling. The structural effects of mutating V348 were investigated based on a previous model of ENaC (44) that was generated on the basis of the published crystal structure of ASIC1, which belongs to the ENaC/degenerin gene family (26) . According to the conformation of the template, the present model is likely to represent a closed conformation of ENaC. Mutants were generated with the Swiss-PdbViewer (49) . Structural analysis and visualization was performed using RasMol (48) .
Statistical methods. Data are presented as means Ϯ SE. N indicates the number of different batches of oocytes, n the number of individual oocytes studied. Statistical significance was assessed using the appropriate version of Student's t-test or one-way ANOVA followed by Dunnett's Multiple Comparison test with GraphPad Prism 4.03 for Windows (GraphPad Software, San Diego, CA).
RESULTS
The ␤V348M mutation stimulates ENaC-mediated wholecell currents in Xenopus laevis oocytes. To study the effect of the ␤V348M mutation on ENaC function, we expressed wild- Fig. 1 . ␤V348M mutation stimulates epithelial sodium channel (ENaC). Wild-type ␣␤␥ENaC (wt) or mutant ␣␤V348M␥ENaC (V348M) was expressed in Xenopus laevis oocytes, and amiloride-sensitive whole-cell currents (⌬Iami) were measured with the two-electrode voltage-clamp technique. A: representative whole-cell current traces of a wild-type and a mutant ENaC-expressing oocyte at a holding potential of Ϫ60 mV. Amiloride (2 M) was present in the bath as indicated by the black bars. B: summary of similar experiments as shown in A performed in wild-type and mutant ENaC-expressing oocytes. C: summary of 5 time course measurements of wild-type and mutant ENaC-expressing oocytes. To correct for batch-tobatch variability, current values were normalized to wild-type control on day 1. Each data point represents mean ⌬Iami measured in 53-62 oocytes. N indicates the number of different batches of oocytes; n or numbers in columns indicate the number of individual oocytes. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001, unpaired t-test.
type ␣␤␥ENaC or mutant ␣␤V348M␥ENaC in Xenopus laevis oocytes and determined amiloride-sensitive whole-cell currents (⌬I ami ) with two-electrode voltage clamp. Figure 1A shows typical whole-cell current traces recorded from a wildtype and a mutant ENaC-expressing oocyte. In 34 different batches of oocytes, ⌬I ami averaged 4.0 Ϯ 0.14 A in ␣␤␥ENaC-expressing control oocytes (n ϭ 331) and 5.6 Ϯ 0.22 A in ␣␤V348M␥ENaC-expressing oocytes (n ϭ 332, P Ͻ 0.001) (Fig. 1B) . Thus on average the ␤V348M mutation stimulated the ENaC-mediated whole-cell Na ϩ current by ϳ38%. In five batches of oocytes, we measured ⌬I ami on three consecutive days following cRNA injection (Fig. 1C) . In wildtype and mutant ENaC-expressing oocytes, ⌬I ami increased from day 1 to day 3, which demonstrates that with longer incubation periods more ENaC protein is synthesized and delivered to the plasma membrane (27) . Importantly, on days 2 and 3, ⌬I ami was significantly higher in mutant than in wildtype ENaC-expressing oocytes, confirming that the stimulatory effect of the ␤V348M mutation on ENaC function is a robust phenomenon. In conclusion, our results demonstrate that the ␤V348M mutation causes an increase in ENaC function.
␤V348M increases channel open probability. The stimulatory effect of the ␤V348M mutation can result from an increased density of channels expressed at the plasma membrane, a higher channel open probability (P o ), or a higher singlechannel conductance. To test whether the ␤V348M mutation increases the average channel P o , we introduced a ␤S520C point mutation into the wild-type and mutant ␤-subunit (14, 22, 24, 36) . Binding of the sulfhydryl reagent MTSET to this cysteine stabilizes the open state of the channel, thereby shifting channel P o close to 1 (28, 52) . Therefore, the ratio of baseline ⌬I ami to ⌬I ami after activation with MTSET provides an estimate of the average channel P o before the application of MTSET. Application of MTSET (1 mM) on ␣␤S520C␥ENaC-expressing oocytes stimulated ⌬I ami ϳ4.2-fold (Fig. 2) , which indicates a P o of ϳ0.24 before the application of MTSET. ⌬I ami of ␣␤V348M-S520C␥ENaC-expressing oocytes was on average ϳ43% higher than that of ␣␤S520C␥ENaC-expressing control oocytes, confirming a stimulatory effect of the ␤V348M mutation in this set of experiments. Application of MTSET to ␣␤V348M-S520C␥ENaC-expressing oocytes stimulated ⌬I ami ϳ3.0-fold, which indicates an average P o of ϳ0.33 before the application of MTSET. These findings support the concept that a higher P o of mutant ENaC contributes to the gain-of-function effect of the mutation. Interestingly, ⌬I ami levels of ␣␤S520C␥ENaC-and ␣␤V348M-S520C␥ENaC-expressing oocytes after MTSET stimulation were comparable. Under the assumption that the single-channel conductance is not affected by the V348M mutation (see below), these findings indicate that an increase in channel surface expression does not contribute to the gain-of-function effect of the ␤V348M mutation.
To investigate whether the ␤V348M mutation alters the single-channel conductance of ENaC and to confirm that it increases P o , we performed single-channel recordings using outside-out patches obtained from oocytes expressing wildtype ␣␤␥ENaC or mutant ␣␤V348M␥ENaC. Figure 3A shows typical single-channel current traces recorded at different holding potentials. The corresponding I/V plots are shown in Fig.  3B . The Goldman-Hodgkin-Katz fits of the data suggest that the wild-type and the mutant channel are sodium selective. In similar experiments, as shown in Fig. 3 , the single-channel conductance of the mutant ENaC averaged 5.20 Ϯ 0.04 pS (n ϭ 7), which is only marginally lower than that of wild-type ENaC averaging 5.4 Ϯ 0.05 pS (n ϭ 6, P Ͻ 0.01). These single-channel conductance values are in good agreement with those previously reported for human ENaC (24, 44, 54) . Thus we have no evidence that an increased single-channel conductance or an altered ion selectivity contribute to the gain-offunction effect of the ␤V348M mutation.
Importantly, our single-channel current recordings demonstrate that the ␤V348M mutation alters the gating kinetics of ENaC. The representative current traces shown in Fig. 3A suggest that the gating kinetics of mutant ENaC are slower than those of wild-type ENaC. To further analyze a possible effect of the mutation on channel gating, we performed additional continuous single-channel recordings at a holding potential of Ϫ70 mV as illustrated in Fig. 4 . At the beginning of these recordings, amiloride was present in the bath solution to determine the current level at which all channels are closed. Washout of amiloride resulted in the appearance of singlechannel current activity. In the absence of amiloride, the average NP o of the mutant ENaC showed a nonsignificant trend to be higher than the average NP o of wild-type ENaC (Fig. 4C) . The maximal number of apparent channel levels (N app ) observed in outside-out patches with mutant ENaC was similar to that observed in outside-out patches with wild-type ENaC (Fig. 4D) . By calculating the ratio of NP o to N app , we estimated the single-channel P o in several recordings similar to those shown in Fig. 4, A and B . On average the P o of mutant ENaC (n ϭ 11) was ϳ61% higher than that of wild-type ENaC (n ϭ 11; P Ͻ 0.05; Fig. 4E ). To further quantify the effect of the ␤V348M on channel gating, we counted the overall number of channel transitions per time as previously described (34) . The average number of channel transitions per second and per N app was largely reduced in outside-out patches with mutant ENaC compared with outside-out patches with wild-type ENaC (Fig. 4F) . Thus, the V348M mutation reduces the frequency of gating events, which is likely to contribute to the observed increase in P o . In summary, our single-channel data confirm that the ␤V348M mutation causes a gain-of-function effect by increasing channel P o . Relative activation of ⌬I ami by chymotrypsin is reduced in mutant ENaC. ENaC can be activated by serine proteases, e.g., chymotrypsin (7, 8, 10, 14, 21, 31, 43, 44, 47) . To test whether the ␤V348M mutation alters the responsiveness of the channel to proteases, we measured the effect of chymotrypsin on ⌬I ami in wild-type ␣␤␥ENaC-and in mutant ␣␤V348M␥ENaC-expressing oocytes. Baseline ⌬I ami of mutant ENaC-expressing oocytes was on average ϳ36% larger than that of wild-type ENaC-expressing control oocytes, consistent with the results reported above. Application of chymotrypsin (2 g/ml) on wild-type ENaC-expressing oocytes stimulated ⌬I ami ϳ4.2-fold (Fig. 5) , which is similar to the stimulatory effect observed with MTSET in oocytes expressing ␣␤S520C␥ENaC without the ␤V348M mutation. In contrast, application of chymotrypsin on mutant ENaC-expressing oocytes stimulated ⌬I ami by only ϳ3.0-fold. This is consistent with the reduced stimulatory effect of MTSET on oocytes expressing ␣␤V348M-S520C␥ENaC. The finding that the relative activation of mutant ENaC by chymotrypsin is lower than that of wild-type ENaC indicates that the average channel P o of the mutant channel is increased. After proteolytic activation, ⌬I ami reached a similar level in wildtype and mutant ENaC-expressing oocytes. Collectively, these findings are in good agreement with the findings obtained in the experiments with MTSET and with our single-channel data. They further support the conclusion that the gain-offunction effect of the ␤V348M mutation is not caused by an increase in channel surface expression but by an increase in average channel P o .
The ENaC activator S3969 stimulates mutant ENaC less than wild-type ENaC.
Recently, S3969 has been identified as a novel small molecule activator of ENaC (36) . At present, the precise mechanism by which S3969 activates ENaC is unknown. However, it has been reported that deletion of V348 in human ␤ENaC abolished the stimulatory effect of the activator. Therefore, we wanted to know whether the ␤V348M mutation reduces the stimulatory effect of S3969. In this set of experiments, ⌬I ami of mutant ENaC-expressing oocytes was on average ϳ29% higher than that of wild-type ENaC-expressing oocytes, consistent with a gain-of-function effect of the ␤V348M mutation. Application of S3969 (10 M) on wild-type ENaCexpressing oocytes activated ⌬I ami ϳ3.5-fold (Fig. 6) . In contrast, superfusion of mutant ENaC-expressing oocytes with S3969 stimulated ⌬I ami ϳ2.6-fold. Thus the stimulatory effect of S3969 on mutant ENaC is smaller than that on wild-type ENaC. Overall the stimulatory effect of S3969 on both wildtype and mutant ENaC was lower than that of MTSET and chymotrypsin. This indicates that S3969, in contrast to MTSET and chymotrypsin, does not fully activate the channel, which is in agreement with the findings of Lu et al. (36) . Nevertheless, our finding that the ␤V348M mutation significantly reduces the stimulatory effect of S3969 is consistent with the interpretation that the mutation increases average channel P o .
Different amino acid substitutions at residue ␤348 show diverse effects on ENaC function. In an additional series of experiments, we investigated whether varying size or charge of residue 348 in ␤ENaC systematically alters ENaC function.
We substituted the wild-type valine in position 348 with amino acids of different size or charge and expressed the individual mutants in oocytes. The results summarized in Fig. 7 demonstrate that, in addition to the V348M mutation, four other mutations (V348G, V348K, V348L, V348W) caused a gainof-function effect with a significantly larger ⌬I ami than that for wild-type ENaC. Interestingly, both the small and nonpolar amino acid glycine (V348G) and the large and positively charged lysine (V348K) stimulated ⌬I ami more than the nonpolar methionine (V348M) with an intermediate size.
The nonpolar leucine (V348L) and the nonpolar tryptophan (V348W) stimulated ENaC less than methionine (V348M). The negatively charged glutamic acid (V348E) had no effect on ENaC function, whereas the negatively charged aspartic acid (V348D) mediated a small but significant inhibitory effect. Interestingly, replacing valine by the polar glutamine (V348Q) or deleting the valine residue (V348del) nearly abolished ENaC function. To test whether these differences result from differences in protein expression, we detected intracellular and biotinylated membrane ␤ENaC levels by Western blot analysis (Fig. 8) . Intracellular ␤ENaC protein expression levels Fig. 8 . Effect of different mutations on intracellular and membrane ␤ENaC protein expression. Oocytes were injected with cRNA for wild-type (wt) ENaC or different ENaC mutants as indicated and incubated for 2 days. Intracellular and surface-expressed membrane protein was separated by SDS-PAGE, and ␤ENaC was detected with a specific antibody. A: representative Western blots from a batch of oocytes. B and C: densitometric analysis of 4 similar Western blots as shown in A. To correct for batchto-batch variability, data were normalized to wild-type control. In addition, signals in B were normalized to a ␤-actin loading control. Numbers in or above columns indicate the number of oocyte batches. **P Ͻ 0.01, ANOVA followed by Dunnett's multiple-comparison test vs. wild-type control.
of the two mutants with the strongest inhibitory effect (V348Q and V348del) were largely reduced (Fig. 8, A and B) , and the corresponding membrane expression signals were hardly distinguishable from background signals (Fig. 8, A and C) . This indicates that a decrease in protein and hence channel surface expression is responsible for the large loss-of-function effect of these two mutations. In contrast, the protein expression level of the other mutants was similar to that of wild-type ␤ENaC both at the plasma membrane and intracellularly. Thus, in these other mutants, the differences in ⌬I ami are probably not the result of differences in channel protein expression but are likely to be caused by differences in channel P o . To test this, we activated all mutants with chymotrypsin, with the exception of the V348Q and V348del mutants, which were not sufficiently expressed to be tested. As shown in Fig. 9A , application of chymotrypsin had a large stimulatory effect on ⌬I ami in all mutants tested. Under the assumption that chymotrypsin maximally activates ENaC, different average P o values of the mutant channels should become apparent by differences in the relative activation of ⌬I ami by chymotrypsin. Figure 9B compares the normalized baseline ⌬I ami before chymotrypsin activation with the relative activation of ⌬I ami by chymotrypsin.
This figure demonstrates that a higher baseline ⌬I ami is related to a lower relative activation by chymotrypsin. This supports the conclusion that the higher baseline currents observed for some of the mutant channels are caused by a higher average P o before chymotrypsin activation. In summary, our data demonstrate that, in most cases, substitution of the ␤V348 residue by another amino acid affects channel function by altering average channel P o . Only in some cases, with largely reduced ENaC currents (V348Q and V348del mutants), the loss-of-function effect was caused by reduced channel surface expression.
To better understand the effects of different amino acid substitutions at ␤V348, we used computational ENaC modeling according to the crystal structure of ASIC1 (26) . Structural analysis of the trimeric ENaC model (Fig. 10A ) reveals that V348 of the ␤-subunit is located within a globular domain (termed palm domain) that is located proximal to the membrane (Fig. 10B) . Interestingly, our model indicates that V348 forms interactions not only within the palm domain but also with the residue M90, which is located in the linker between the palm and the ␤-ball domain (Figs. 10B and 11A ). Molecular modeling reveals that the majority of the mutations investigated destabilize the structure of the closed ENaC for the following reasons: The lack of the side chain in the V348G mutant results in a loss of the contacts to M90 (Fig. 11B) , thereby reducing the stability of the corresponding region. A mutation to lysine (V348K) is unfavorable because of steric clashes with M90 and electrostatic repulsion with K350 (Fig. 11C) . Clashes of residue 348 with M90 are also observed for V348M (Fig. 11D) , as well as V348L and V348W (data not shown). In summary, all mutants described above are either characterized by a loss of contact with M90 or by steric clashes with M90. Both effects are energetically unfavorable and are expected to destabilize the interaction between the palm and the ␤-ball domain (Fig.  10B) . In contrast, a mutation to glutamate or aspartate allows the formation of a novel stabilizing salt-bridge with K350 (Fig. 11E) . This may explain why mutating valine to glutamate or aspartate in this position has no stimulatory effect on the channel. Interestingly, the same type of interaction is also observed in the crystal structure of the homologous ASIC1 channel (Fig. 11F) .
The ␤V348M mutation stimulates ENaC-mediated wholecell currents in HEK293 cells. To rule out that the gain-offunction effect of the ␤V348M mutation is limited to the Xenopus laevis oocyte expression system, we transiently transfected HEK293 cells with wild-type ␣␤␥ENaC or mutant ␣␤V348M␥ENaC and measured amiloride-sensitive wholecell currents using the patch-clamp technique. Figure 12A shows representative whole-cell current recordings from a cell expressing wild-type ENaC and a cell expressing mutant ENaC. ⌬I ami averaged 85 Ϯ 15 pA (n ϭ 15) in wild-type ENaC-expressing cells and 157 Ϯ 26 pA (n ϭ 12, P Ͻ 0.05) in mutant ENaC-expressing cells. To correct for differences in cell size, current density was calculated. Current density averaged 8.0 Ϯ 1.3 pA/pF (n ϭ 15) in wild-type ENaC-expressing cells and 14.8 Ϯ 2.4 pA/pF (n ϭ 12, P Ͻ 0.05) in mutant ENaC-expressing cells (Fig. 12B) . These results indicate that the ␤V348M mutation also causes a gain-of-function effect in mammalian cells. Fig. 3 . Data were pooled from 47 oocytes for wild-type and ␤V348M-ENaC and from 21-24 oocytes for the remaining mutants. To correct for batch-to-batch variability, data were normalized to mean ⌬Iami of wild-type ENaC-expressing oocytes before chymotrypsin activation. B: same data as in A. The relative chymotrypsin activation was calculated as the ratio of ⌬Iami after and before chymotrypsin activation and plotted against basal ⌬Iami before chymotrypsin activation. 
DISCUSSION
In the present study, we investigated the effect of a mutation in ␤ENaC (␤V348M) on channel function. To the best of our knowledge, this is the first report on the functional effects of this mutation identified in a patient with severe CF-like symptoms (39) . In the Xenopus laevis oocyte expression system, we found that the ␤V348M mutation stimulated ENaC whole-cell currents by ϳ40%. Using different experimental approaches, including single-channel recordings, we demonstrated that this gain-of-function effect is caused by an increased P o of the mutant channel. Moreover, we used transiently transfected HEK293 cells to confirm the gain-of-function effect of the ␤V348M mutation in a mammalian expression system. Our findings suggest that the gain-of-function effect of the ␤V348M mutation may contribute to CF pathophysiology by inappropriately increasing sodium and fluid absorption in the respiratory tract of affected patients.
Functional testing of the effect of the ␤V348M-ENaC mutation in the present study was performed in Xenopus laevis oocytes, a well-established heterologous expression system for the investigation of ion channels. The use of the oocyte expression system to evaluate the effect of a mutation on channel function requires some precautions to avoid misinterpretation of data. In particular, the batch-to-batch variability of channel expression in oocytes is a well-known phenomenon. To address this, we systematically used matched oocytes from the same batch when comparing the activity of wild-type and mutant channels and repeated the experiments in several batches of oocytes. There is also a batch-to-batch variability in cRNA quality, which may have an impact on protein expression levels and thus whole-cell currents. To minimize the risk of expression artifacts, we synthesized all cRNAs for wild-type and corresponding mutants in parallel, and experiments were repeated with at least two different batches of cRNA. Importantly, we checked protein expression by Western blot analysis and confirmed that the expression levels of wild-type and ␤V348M-ENaC were similar. The importance of verifying protein expression levels is further illustrated by the finding that the loss-of-function effect of the V348Q and the V348del mutation could be attributed to reduced protein expression of the mutant channels.
We estimated average channel P o by comparing whole-cell currents after activation of ␤S520C-ENaC by MTSET to those before activation. With this well-established approach (14, 20, 22, 24, 36) , P o can be estimated under the assumption that all channels are fully activated by MTSET. We previously observed in outside-out patches from oocytes expressing rat ␣␤S518C␥ENaC (corresponds to human ␣␤S520C␥ENaC) that MTSET increased the P o of active channels in the patch close to one and that subsequent application of trypsin was able to activate additional so-called near-silent channels (14) . This suggested that activation of near-silent channels requires proteolytic processing of the channel and that MTSET is not able to activate near-silent channels in the same way as trypsin. In contrast, in the present study, MTSET stimulated ENaC to the same extent as chymotrypsin, known to fully activate ENaC, including the recruitment of near-silent channels (44) . This indicates that MTSET not only increases the P o of channels that are already active but can also activate a population of near-silent channels. This different response of human ENaC to MTSET compared with that of rat ENaC (14) may be explained by species-specific differences of ENaC gating (29) . MTSET is thought to bind to the channel only when it is in the open conformation (28, 52) . Therefore, near-silent channels are unlikely to be activated by MTSET unless they occasionally show spontaneous openings that are long enough for MTSET to act on the channel (14) . It is conceivable that near-silent human ENaC opens more frequently and with slightly longer open times than rat ENaC, which may explain its greater responsiveness to MTSET.
In the present study, chymotrypsin activated wild-type and ␤V348M-ENaC ϳ4.2-fold and ϳ3.0-fold, respectively. However, in previous studies on primary human nasal epithelia (17) or human bronchial epithelial cells (4, 11) , trypsin failed to activate ENaC, which suggests that in these epithelia ENaC is already fully cleaved and active under resting conditions. In the oocyte expression system, the current levels of wild-type and ␤V348M-ENaC were similar after full stimulation with chymotrypsin. Thus, in respiratory epithelia with high protease activity and full proteolytic activation of all ENaCs present at the plasma membrane, the ␤V348M mutation may not result in a gain-of-function phenotype. However, it has been demonstrated that the effect of trypsin on ENaC in cell layers of respiratory epithelia depends on the experimental conditions used (40, 56) . Prolonged equilibration periods in the Ussing chamber are thought to wash out endogenous protease inhibitors from the ASL, leading to disinhibition of proteases and hence to proteolytic ENaC activation. In contrast, shortly after changing the epithelial cell layers from the air-liquid interface to the Ussing chambers, trypsin has been shown to have a stimulatory effect on ENaC (5, 40) . This latter situation is likely to reflect the situation in vivo at least under certain physiological conditions. Thus the gain-of-function effect of the V348M mutation may well be relevant in native respiratory epithelia.
The presence of V348 in ␤ENaC was reported by Lu et al. (36) to be essential for the stimulatory effect of the novel small molecule ENaC activator S3969. This was concluded from the finding that deletion of ␤V348 abolished the stimulatory effect of S3969 on ENaC. We were unable to reproduce this finding because of an insufficient expression of the ␤V348del mutant at the oocyte membrane. We confirmed the stimulatory effect of S3969 on wild-type ENaC described by Lu et al. (36) , but the stimulatory effects of chymotrypsin and MTSET on ENaC were larger than that of S3969. This suggests that S3969 did not fully activate ENaC under our experimental conditions. A likely explanation for this finding is that the S3969 concentration used in the present study (10 M) was not sufficient to achieve a maximal stimulation. Indeed, Lu et al. (36) reported a maximal stimulation of ENaC by S3969 at a threefold higher concentration (30 M) (36) than that used in the present study. Importantly, ␤V348M-ENaC could also be stimulated by S3969. This demonstrates that the ␤V348M mutation has no impact on the stimulatory effect of S3969 on ENaC.
To further elucidate the molecular mechanism by which the ␤V348M mutation causes an increase in average channel P o , we tested the functional effect of different amino acid substitutions at the ␤V348 residue on ENaC function. Interestingly, substitution of the ␤V348 residue by several amino acids resulted in ENaC stimulation. However, this effect could not be correlated to the size or charge of the amino acids. Therefore, we used computational channel modeling to analyze the putative microdomain around ␤V348. The results of this modeling suggest a qualitative correlation between the structural effect of the mutants and the observed effect on ⌬I ami . Mutants that destabilize the closed ENaC structure (V348 ¡ G, K, M, L, W) generally result in increased ⌬I ami , whereas stabilizing mutants do not affect (V348E) or even reduce ⌬I ami (V348D). Therefore, it is tempting to speculate that mutants at position 348 that destabilize the closed ENaC conformation facilitate the closed to open transition, thereby increasing the open probability of the channel. This may also explain our experimental finding that the ␤V348M mutation reduced the number of channel transitions per second in single-channel recordings. A thorough structural interpretation of this effect, however, has to await the crystal structure of an open channel, which is currently not available.
Epithelia of conducting airways are covered by a mucus layer, which not only prevents desiccation but also scavenges inhaled particles. The mucus layer floats on a liquid or gel-like layer, the so-called periciliary layer (PCL), and is transported by cilia to the pharynx, where it is removed from the airways by coughing or swallowing, a process termed mucociliary clearance. Together, the mucus layer and the PCL are often referred to as the ASL layer (6) . A well-defined microenvironment is essential for proper cilia function. In cultured human airway epithelial cells from healthy donors, the PCL was found to have the same height as that of outstretched cilia (ϳ7 m), whereas the height of the PCL was largely reduced (ϳ3 m) in cultured airway epithelial cells from patients with CF (38) . Flattening of the PCL leads to steric hindrance of the cilia and thus impairs mucociliary clearance (32) . Precise regulation of ASL volume is therefore an important prerequisite for proper lung defense. Interestingly, PCL height was similar in excised tracheal epithelia from newborn non-CF and CFTR Ϫ/Ϫ pigs, which had not yet developed airway inflammation (9) . Thus it is still unclear whether flattening of the PCL in patients with CF occurs before the onset of inflammation or whether inflammation occurs first and affects transepithelial electrolyte transport, which then reduces PCL height. The gain-of-function effect of the ␤V348M mutation could favor disease in both situations. On the one hand, increased Na ϩ absorption via overactive ENaC could flatten the PCL and thus reduce mucociliary clearance. On the other hand, the ␤V348M mutation could increase the vulnerability of airway epithelia to inflammatory processes by reducing the threshold for development of CF symptoms and thus influence the manifestation and intensity of the disease. In this context, it is of interest that the patient reported by Mutesa et al. (39) was compound heterozygous for the ␤V348M mutation and a F693L-CFTR mutation. The F693L-CFTR mutation was described as a polymorphism that, compared with wild-type CFTR, did not affect channel maturation in COS1 cells or chloride transport ability in oocytes (57) . Therefore, it seems unlikely that the F693L-CFTR mutation alone is sufficient to cause the disease. However, in combination with the ␤V348M-ENaC gain-of-function mutation, it may contribute to the development and/or manifestation of CF disease.
In summary, we have shown that the ␤V348M mutation found in a patient with severe CF-like symptoms (39) stimulates ENaC activity by an increase in average channel P o . The underlying mechanism for this increase is probably a destabilization of the closed channel state by the mutation. Our finding that the ␤V348M mutation has a gain-of-function effect may provide an explanation for the symptoms of the affected patient according to the pathophysiological concept that elevated Na ϩ transport reduces mucociliary clearance in respiratory epithelia and favors CF-like pulmonary symptoms. However, additional factors may contribute to the patient's phenotype, and further studies are needed to elucidate the role of ENaC in the pathophysiology of CF.
